Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Michael A. Kamm(The University of Melbourne), Raymond E. Joseph(Takeda (United States)), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Todd Butler(Takeda (United States)), David D. Stephenson(Basingstoke and North Hampshire Hospital), L Jackowski, Andrew Lyne(Basingstoke and North Hampshire Hospital), M A Gassull(Unknown), Mary Palmen(Basingstoke and North Hampshire Hospital), William J. Sandborn(University of San Diego)
Cited by 352
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k